CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | EC 2.5.1.18 (glutathione transferase) inhibitor |
|
Accession: | CHEBI:76797
|
browse the term
|
Definition: | An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of a glutathione transferase (EC 2.5.1.18). |
Synonyms: | related_synonym: | EC 2.5.1.18 inhibitor; EC 2.5.1.18 inhibitors; RX:glutathione R-transferase inhibitor; RX:glutathione R-transferase inhibitors; S-(hydroxyalkyl)glutathione lyase inhibitor; S-(hydroxyalkyl)glutathione lyase inhibitors; glutathione S-alkyl transferase inhibitor; glutathione S-alkyl transferase inhibitors; glutathione S-alkyltransferase inhibitor; glutathione S-alkyltransferase inhibitors; glutathione S-aralkyltransferase inhibitor; glutathione S-aralkyltransferase inhibitors; glutathione S-aryltransferase inhibitor; glutathione S-aryltransferase inhibitors; glutathione S-transferase inhibitor; glutathione S-transferase inhibitors; glutathione transferase (EC 2.5.1.18) inhibitors; glutathione transferase inhibitor; glutathione transferase inhibitors |
| xref: | Wikipedia:Glutathione_S-transferase |
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
acteoside results in decreased expression of ACTA2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of AGER mRNA; acteoside results in decreased expression of AGER protein acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER mRNA]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER protein] |
CTD |
PMID:33522686 PMID:36112883 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases localization |
ISO |
acteoside promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] acteoside results in decreased localization of AHR protein |
CTD |
PMID:21756928 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
ISO |
acteoside results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions decreases secretion |
ISO |
acteoside results in decreased expression of CCL2 mRNA acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] acteoside results in decreased secretion of CCL2 protein |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCNE1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions decreases expression |
ISO |
acteoside inhibits the reaction [HMGB1 protein results in increased expression of and results in increased activity of CDC42 protein]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of CDC42 mRNA]; acteoside results in decreased expression of and results in decreased activity of CDC42 protein acteoside results in decreased expression of CDC42 mRNA |
CTD |
PMID:36112883 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
acteoside results in increased expression of CDH1 protein |
CTD |
PMID:33522686 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
acteoside results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases activity multiple interactions |
ISO |
acteoside results in decreased activity of CDK4 protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein]; acteoside results in decreased expression of and results in decreased activity of CDK6 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1A mRNA; acteoside results in increased expression of CDKN1A protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1B mRNA; acteoside results in increased expression of CDKN1B protein acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases secretion decreases expression multiple interactions |
ISO |
acteoside results in decreased secretion of CXCL10 protein acteoside results in decreased expression of CXCL10 mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
acteoside results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
acteoside inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:14672760 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of EGFR protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of HMGB1 mRNA; acteoside results in decreased expression of HMGB1 protein acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER mRNA]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER protein]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of and results in increased activity of CDC42 protein]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of CDC42 mRNA] |
CTD |
PMID:33522686 PMID:36112883 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of ICAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of IFNG mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21371465 PMID:21756928 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] acteoside results in decreased expression of IL6 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB2 protein] |
CTD |
PMID:16393473 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of MAPK1 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein] acteoside results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO |
acteoside results in decreased phosphorylation of MAPK3 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein] acteoside results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nox1 |
NADPH oxidase 1 |
decreases activity |
ISO |
acteoside results in decreased activity of NOX1 protein |
CTD |
PMID:16393473 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Ptgds |
prostaglandin D2 synthase |
affects binding |
ISO |
acteoside binds to PTGDS protein |
CTD |
PMID:26456343 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[acteoside co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
Verbascoside decreases expression of RAC1 mRNA in colon cancer cells |
RGD |
PMID:29886834 |
RGD:153298971 |
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of RB1 protein [acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of RELA protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] acteoside results in decreased phosphorylation of RELA protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Smad2 |
SMAD family member 2 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD2 protein |
CTD |
PMID:17634406 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad7 |
SMAD family member 7 |
increases expression |
ISO |
acteoside results in increased expression of SMAD7 protein |
CTD |
PMID:33522686 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
acteoside results in decreased expression of SNAI1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
acteoside results in decreased expression of SNAI2 protein |
CTD |
PMID:33522686 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
acteoside results in decreased expression of SOD2 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[acteoside co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
acteoside results in increased expression of TGFB1 mRNA |
CTD |
PMID:17634406 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
decreases expression |
ISO |
acteoside results in decreased expression of TGFBR1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
decreases expression |
ISO |
acteoside results in decreased expression of TGFBR2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of VCAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
Bongkrekic Acid results in increased expression of ADIPOQ mRNA |
CTD |
PMID:25786526 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
Bongkrekic Acid inhibits the reaction [leflunomide results in increased expression of ATF4 protein] |
CTD |
PMID:29427785 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Bongkrekic Acid inhibits the reaction [leflunomide results in increased expression of DDIT3 protein] |
CTD |
PMID:29427785 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Bongkrekic Acid inhibits the reaction [N-caproylsphingosine results in increased expression of ICAM1 mRNA] |
CTD |
PMID:12952965 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il24 |
interleukin 24 |
decreases activity |
ISO |
Bongkrekic Acid results in decreased activity of IL24 protein |
CTD |
PMID:14678967 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
Bongkrekic Acid inhibits the reaction [[Diamide co-treated with Glutathione] results in increased activity of MGST1 protein] |
CTD |
PMID:18634816 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
increases activity |
ISO |
Bongkrekic Acid results in increased activity of P2RX1 protein |
CTD |
PMID:34019862 |
|
NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
|
|
G |
Padi4 |
peptidyl arginine deiminase 4 |
increases activity |
ISO |
Bongkrekic Acid results in increased activity of PADI4 protein |
CTD |
PMID:34019862 |
|
NCBI chr 5:153,041,351...153,074,412
Ensembl chr 5:153,041,352...153,074,362
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity |
ISO |
Bongkrekic Acid analog results in increased activity of PPARG protein; Bongkrekic Acid results in increased activity of PPARG protein |
CTD |
PMID:25786526 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Slc25a4 |
solute carrier family 25 member 4 |
multiple interactions |
EXP |
Bongkrekic Acid inhibits the reaction [oxophenylarsine binds to SLC25A4 protein] |
CTD |
PMID:18667415 |
|
NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733
|
|
G |
Slc25a5 |
solute carrier family 25 member 5 |
decreases activity |
ISO |
Bongkrekic Acid results in decreased activity of SLC25A5 protein |
CTD |
PMID:26746582 |
|
NCBI chr X:116,031,896...116,034,963
Ensembl chr X:116,031,803...116,034,967
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of ABCC1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of ABCC2 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of ACHE protein |
CTD |
PMID:20854806 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of ACLY mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:23146752 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Rotenone results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:36048341 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] Chlorogenic Acid affects the reaction [2,2'-azobis(2-amidinopropane) results in increased degradation of ALB protein] |
CTD |
PMID:11322927 PMID:23146752 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of AQP1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of AQP3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Ar |
androgen receptor |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of AR mRNA |
CTD |
PMID:20706672 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF4 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of ATF6 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF6 protein] |
CTD |
PMID:34801538 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of BAMBI mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of BAMBI protein] |
CTD |
PMID:23146752 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in increased expression of BAX protein]; Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of BAX mRNA] Chlorogenic Acid results in increased expression of BAX mRNA; Chlorogenic Acid results in increased expression of BAX protein Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of BAX protein] |
CTD |
PMID:25043994 PMID:28479099 PMID:28623112 PMID:33058431 PMID:33242462 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] Chlorogenic Acid results in decreased expression of BCL2 mRNA; Chlorogenic Acid results in decreased expression of BCL2 protein Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of BCL2 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of BCL2 mRNA] |
CTD |
PMID:28479099 PMID:28623112 PMID:33058431 PMID:33242462 PMID:34801538 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Canx |
calnexin |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of CANX protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CANX protein] |
CTD |
PMID:34801538 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CASP12 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of CASP3 mRNA]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein] Chlorogenic Acid results in increased expression of CASP3 mRNA Chlorogenic Acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of CASP3 protein] |
CTD |
PMID:25043994 PMID:28479099 PMID:33058431 PMID:33242462 PMID:34801538 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [aluminum chloride results in increased expression of CASP8 protein] |
CTD |
PMID:28623112 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of CASP9 protein] |
CTD |
PMID:28479099 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased activity of CAT protein] Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of CAT mRNA] |
CTD |
PMID:28479099 PMID:28623112 PMID:31390532 PMID:33242462 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of CCL2 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of CCL2 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:26079055 PMID:31306686 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of CCND1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of CD44 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of CDH1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of COL1A1 mRNA Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA] |
CTD |
PMID:20706672 PMID:23146752 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cs |
citrate synthase |
increases activity |
ISO |
Chlorogenic Acid results in increased activity of CS protein |
CTD |
PMID:31306686 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of CXCL1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of CXCL1 protein] |
CTD |
PMID:26079055 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cygb |
cytoglobin |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of CYGB mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of CYP19A1 protein |
CTD |
PMID:29899696 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of CYP2E1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of DDIT3 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of DDIT3 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dsg3 |
desmoglein 3 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of DSG3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:11,799,355...11,830,988
Ensembl chr18:11,798,900...11,830,818
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of EGF mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of EIF2AK3 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of ERN1 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:34801538 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ERO1A protein] |
CTD |
PMID:34801538 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
EXP |
Chlorogenic Acid results in decreased expression of ESR1 protein |
CTD |
PMID:29899696 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of ESR2 protein |
CTD |
PMID:29899696 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F10 |
coagulation factor X |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of F10 protein |
CTD |
PMID:27704645 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of F2 protein |
CTD |
PMID:27704645 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbn1 |
fibrillin 1 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FBN1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbn2 |
fibrillin 2 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FBN2 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:51,499,670...51,703,976
Ensembl chr18:51,499,737...51,703,976
|
|
G |
Ffar1 |
free fatty acid receptor 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Rotenone results in decreased expression of FFAR1 mRNA] |
CTD |
PMID:36048341 |
|
NCBI chr 1:86,111,368...86,112,272
Ensembl chr 1:86,111,368...86,112,272
|
|
G |
Ffar2 |
free fatty acid receptor 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Rotenone results in decreased expression of FFAR2 mRNA] |
CTD |
PMID:36048341 |
|
NCBI chr 1:86,071,855...86,075,049
Ensembl chr 1:86,072,184...86,075,033
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of FGF1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of FSHB protein] |
CTD |
PMID:33242462 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of FSHR protein |
CTD |
PMID:29899696 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Gcg |
glucagon |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Rotenone] results in increased secretion of GCG protein |
CTD |
PMID:36048341 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased expression of GCLC mRNA Chlorogenic Acid promotes the reaction [Acetaminophen results in increased expression of GCLC mRNA] |
CTD |
PMID:29136249 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of GCLM mRNA |
CTD |
PMID:29136249 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Rotenone results in decreased expression of GLP1R protein] |
CTD |
PMID:36048341 |
|
NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions decreases expression |
EXP ISO |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased activity of GPT protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] Chlorogenic Acid results in decreased expression of GPT protein Chlorogenic Acid inhibits the reaction [aluminum chloride results in increased activity of GPT protein] |
CTD |
PMID:28479099 PMID:28623112 PMID:31390532 PMID:33058431 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] |
CTD |
PMID:33242462 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grn |
granulin precursor |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of GRN mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Rotenone results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:36048341 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased activity of GSR protein] Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of GSR mRNA] |
CTD |
PMID:28479099 PMID:33242462 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases activity |
ISO |
Chlorogenic Acid results in increased activity of GSTA1 protein |
CTD |
PMID:15944151 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Has1 |
hyaluronan synthase 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of HAS1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 1:58,693,411...58,705,653
Ensembl chr 1:58,693,411...58,705,397
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases expression |
EXP ISO |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] Chlorogenic Acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:20696151 PMID:21870829 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of HMOX1 protein] Chlorogenic Acid results in increased expression of HMOX1 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 protein] |
CTD |
PMID:25043994 PMID:29136249 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of HSPA5 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of HSPA5 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of HSPB1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of IL1A mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B mRNA] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of IL1B mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of IL1B protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] |
CTD |
PMID:23146752 PMID:24709313 PMID:26079055 PMID:33242462 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of IL6 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of IL6 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL6 protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 mRNA] |
CTD |
PMID:21870829 PMID:23146752 PMID:26079055 PMID:31390532 PMID:33242462 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression multiple interactions |
EXP |
Chlorogenic Acid results in decreased expression of ITGB2 protein Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of ITGB2 protein] |
CTD |
PMID:21414398 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of JUN protein] |
CTD |
PMID:15944151 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Krt5 |
keratin 5 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of KRT5 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] |
CTD |
PMID:20696151 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of LHB protein] |
CTD |
PMID:33242462 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] |
CTD |
PMID:20696151 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAP2K4 protein] |
CTD |
PMID:15944151 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] Chlorogenic Acid promotes the reaction [Acetaminophen results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:15944151 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] Chlorogenic Acid promotes the reaction [Acetaminophen results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:34801538 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mc1r |
melanocortin 1 receptor |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of MC1R mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:51,452,448...51,455,375
Ensembl chr19:51,453,239...51,454,192
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Chlorogenic Acid results in decreased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of MPO protein] |
CTD |
PMID:26079055 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of COX1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Zymosan] results in decreased expression of COX2 protein; Chlorogenic Acid inhibits the reaction [Zymosan results in increased expression of COX2 protein] |
CTD |
PMID:30481570 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MT1 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MT1 protein] |
CTD |
PMID:31390532 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of MYD88 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of MYD88 protein] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of MYD88 protein] |
CTD |
PMID:23146752 PMID:26079055 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases localization multiple interactions increases response to substance affects localization decreases response to substance |
ISO |
Chlorogenic Acid results in increased localization of NFE2L2 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein]; [Chlorogenic Acid co-treated with Acetaminophen] results in increased activity of and affects the localization of NFE2L2 protein; [Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein; U 0126 inhibits the reaction [[Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] [Chlorogenic Acid co-treated with Acetaminophen] affects the localization of and results in increased activity of NFE2L2 protein; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2 mRNA] NFE2L2 results in increased susceptibility to Chlorogenic Acid Chlorogenic Acid affects the localization of NFE2L2 protein NFE2L2 gene mutant form results in decreased susceptibility to Chlorogenic Acid |
CTD |
PMID:15944151 PMID:29136249 PMID:33242462 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:20026373 PMID:23146752 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of NFKBIB protein] |
CTD |
PMID:20026373 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of NOS2 mRNA]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of NOS2 protein] |
CTD |
PMID:20026373 PMID:23146752 PMID:28479099 PMID:31306686 PMID:33242462 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of NOS3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of NPPB protein] |
CTD |
PMID:34801538 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased activity of NQO1 protein Chlorogenic Acid results in increased expression of NQO1 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of NQO1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of NQO1 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases expression increases activity |
ISO |
Chlorogenic Acid results in increased expression of NR1H4 mRNA Chlorogenic Acid results in increased activity of NR1H4 protein |
CTD |
PMID:36542898 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OCLN mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OCLN protein] |
CTD |
PMID:31390532 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of P4HB protein] |
CTD |
PMID:34801538 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Chlorogenic Acid promotes the reaction [Cisplatin results in increased expression of PCNA protein] |
CTD |
PMID:25043994 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PECAM1 protein] |
CTD |
PMID:21414398 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pgr |
progesterone receptor |
increases expression decreases expression |
ISO |
Chlorogenic Acid results in increased expression of PGR mRNA Chlorogenic Acid results in decreased expression of PGR mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased expression of PIK3R1 mRNA Chlorogenic Acid inhibits the reaction [Rotenone results in decreased phosphorylation of PIK3R1 protein] |
CTD |
PMID:21870829 PMID:36048341 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of PLOD3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression decreases expression |
ISO |
Chlorogenic Acid results in increased expression of PPARG mRNA Chlorogenic Acid results in decreased expression of PPARG mRNA |
CTD |
PMID:20706672 PMID:21870829 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Acetaminophen] results in decreased expression of PPP2R1A protein |
CTD |
PMID:29136249 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Acetaminophen] results in decreased expression of PPP5C protein |
CTD |
PMID:29136249 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of PTGS2 protein] Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of and results in increased expression of PTGS2 protein] |
CTD |
PMID:20026373 PMID:23146752 PMID:25043994 PMID:28479099 PMID:31306686 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of RAD23A mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of RARA mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of and results in increased phosphorylation of and affects the localization of RELA protein]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein] |
CTD |
PMID:20026373 PMID:26079055 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retreg1 |
reticulophagy regulator 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in decreased expression of RETREG1 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 2:76,335,609...76,474,817
Ensembl chr 2:76,335,609...76,493,898
|
|
G |
Rtn3 |
reticulon 3 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of RTN3 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 1:204,612,675...204,669,212
Ensembl chr 1:204,612,675...204,669,275
|
|
G |
Rxra |
retinoid X receptor alpha |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of RXRA mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Sec62 |
SEC62 homolog, preprotein translocation factor |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of SEC62 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 2:112,570,810...112,598,198
Ensembl chr 2:112,570,819...112,601,814
|
|
G |
Sell |
selectin L |
multiple interactions |
EXP |
[Chlorogenic Acid co-treated with lipopolysaccharide, E. coli O26-B6] results in increased expression of SELL protein; Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of SELL protein] |
CTD |
PMID:21414398 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC11A2 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC11A2 protein] |
CTD |
PMID:31390532 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in decreased expression of SLC22A2 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of SLC2A4 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Chlorogenic Acid inhibits the reaction [Rotenone results in increased phosphorylation of SNCA protein] |
CTD |
PMID:36048341 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased expression of SOD2 mRNA Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] |
CTD |
PMID:33242462 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of SOD3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of SQSTM1 protein] |
CTD |
PMID:29136249 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of SRD5A2 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of STAR protein |
CTD |
PMID:29899696 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TJP1 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TJP1 protein] |
CTD |
PMID:31390532 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TLR3 protein] |
CTD |
PMID:26079055 |
|
NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TLR4 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TLR4 protein] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TLR4 protein] |
CTD |
PMID:23146752 PMID:26079055 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of TNF mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of TNF protein]; Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of TNF protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA] |
CTD |
PMID:21870829 PMID:23146752 PMID:25043994 PMID:26079055 PMID:31306686 PMID:31390532 PMID:33242462 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of TRP53 protein] Chlorogenic Acid results in increased expression of TRP53 mRNA |
CTD |
PMID:25043994 PMID:33058431 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of TPT1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of TRAF2 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of TXN mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Tyr |
tyrosinase |
increases oxidation multiple interactions |
ISO |
TYR protein results in increased oxidation of Chlorogenic Acid [TYR protein results in increased oxidation of Chlorogenic Acid] which results in decreased abundance of Glutathione |
CTD |
PMID:20685355 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of TYRP1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of UGT1A1 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation decreases activity |
ISO |
UGT1A3 protein results in increased glucuronidation of Chlorogenic Acid Chlorogenic Acid results in decreased activity of UGT1A3 protein |
CTD |
PMID:15117964 PMID:35868516 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of UGT1A6 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of UGT1A9 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of UGT2B17 protein |
CTD |
PMID:35868516 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of UGT2B7 protein |
CTD |
PMID:35868516 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of XBP1 mRNA] |
CTD |
PMID:34801538 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
caffeic acid results in increased phosphorylation of and results in decreased activity of ACACA protein |
CTD |
PMID:28576465 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP |
caffeic acid inhibits the reaction [Caffeine results in decreased activity of ACHE protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of ACHE protein] |
CTD |
PMID:28465162 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of ACLY protein |
CTD |
PMID:28576465 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions decreases activity |
ISO |
[caffeic acid results in decreased activity of ALOX15 protein] inhibits the reaction [vorinostat results in increased activity of CASP3 protein]; [caffeic acid results in decreased activity of ALOX15 protein] which results in decreased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [caffeic acid results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; caffeic acid inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of ALOX15 protein] |
CTD |
PMID:10904086 PMID:11406566 PMID:15574791 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]; caffeic acid inhibits the reaction [Hydrogen Peroxide affects the localization of ALOX5 protein] caffeic acid inhibits the reaction [aluminum chloride results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [aluminum chloride results in increased expression of ALOX5 protein] |
CTD |
PMID:18482095 PMID:18951527 PMID:27368151 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [aluminum chloride results in increased expression of APP protein modified form]; caffeic acid inhibits the reaction [aluminum chloride results in increased expression of APP protein] |
CTD |
PMID:18482095 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg1 |
arginase 1 |
decreases activity |
ISO |
caffeic acid results in decreased activity of ARG1 protein |
CTD |
PMID:27378625 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of ATP6V0D2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
[caffeic acid results in decreased activity of ALOX15 protein] inhibits the reaction [vorinostat results in increased activity of CASP3 protein] caffeic acid inhibits the reaction [Valproic Acid results in increased expression of CASP3 protein] |
CTD |
PMID:15574791 PMID:29968957 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP ISO |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; caffeic acid inhibits the reaction [Nickel results in decreased activity of CAT protein] caffeic acid results in increased activity of CAT protein caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CAT protein results in increased metabolism of Hydrogen Peroxide]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein] |
CTD |
PMID:18405891 PMID:21640567 PMID:22036979 PMID:27378625 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL2 mRNA; caffeic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:16806235 PMID:31306686 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL3 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR1 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR2 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Cd4 |
Cd4 molecule |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CD4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 4:157,668,878...157,695,366
Ensembl chr 4:157,668,878...157,695,191
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CD68 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of CDC20 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of CDK2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [aluminum chloride results in decreased expression of CHAT protein] |
CTD |
PMID:18482095 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO |
COMT protein results in increased methylation of caffeic acid |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Malathion results in decreased expression of CRH mRNA] |
CTD |
PMID:25404496 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of CTF1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased activity of CTSB protein] |
CTD |
PMID:20391626 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol affects the activity of CTSD protein] |
CTD |
PMID:20391626 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of CXCL2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine] |
CTD |
PMID:7710944 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dap |
death-associated protein |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of DAP mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of DNAJB11 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of DPYSL4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of EDN1 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
caffeic acid affects the reaction [Acetaminophen results in increased expression of and affects the localization of EGR1 protein]; caffeic acid inhibits the reaction [Acetaminophen results in increased expression of EGR1 mRNA] |
CTD |
PMID:27720869 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elmo2 |
engulfment and cell motility 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of ELMO2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185
|
|
G |
Erf |
Ets2 repressor factor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of ERF mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:80,829,935...80,838,388
Ensembl chr 1:80,829,935...80,838,388
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of F3 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fasn |
fatty acid synthase |
decreases expression multiple interactions |
ISO |
caffeic acid results in decreased expression of FASN mRNA [Metformin co-treated with caffeic acid] results in decreased expression of FASN protein |
CTD |
PMID:21870829 PMID:28576465 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Flrt2 |
fibronectin leucine rich transmembrane protein 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of FLRT2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of FLT4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
caffeic acid results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of GADD45A mRNA]; caffeic acid inhibits the reaction [Acetaminophen results in increased expression of GADD45A protein] |
CTD |
PMID:27720869 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol affects the activity of GLB1 protein] |
CTD |
PMID:20391626 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gls |
glutaminase |
increases expression |
ISO |
caffeic acid results in increased expression of GLS protein |
CTD |
PMID:28576465 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GOT1 protein] |
CTD |
PMID:15212457 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein] caffeic acid inhibits the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:15212457 PMID:27720869 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of GSR protein] caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein] caffeic acid promotes the reaction [Thapsigargin results in decreased expression of GSR mRNA] |
CTD |
PMID:19442820 PMID:21640567 PMID:22036979 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTM1 protein |
CTD |
PMID:8340025 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTM2 protein |
CTD |
PMID:8340025 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTP1 protein |
CTD |
PMID:8340025 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:20391626 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
H6pd |
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of H6PD protein] |
CTD |
PMID:21640567 |
|
NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171
|
|
G |
Havcr2 |
hepatitis A virus cellular receptor 2 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of HAVCR2 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:30,882,484...30,914,018
Ensembl chr10:30,882,606...30,909,137
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of HES1 mRNA] |
CTD |
PMID:29968957 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
caffeic acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
caffeic acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of HSP90B1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of HSPE1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of IFNG protein caffeic acid inhibits the reaction [Valproic Acid results in increased expression of IFNG protein] |
CTD |
PMID:27378625 PMID:29968957 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
caffeic acid results in decreased expression of IL10 protein |
CTD |
PMID:27378625 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of IL1B protein] caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein] |
CTD |
PMID:27368151 PMID:27720869 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
caffeic acid results in increased expression of IL2 protein |
CTD |
PMID:27378625 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il21r |
interleukin 21 receptor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of IL21R mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:180,168,028...180,195,690
Ensembl chr 1:180,168,097...180,195,522
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
caffeic acid results in decreased expression of IL4 protein |
CTD |
PMID:27378625 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of IL6 mRNA caffeic acid inhibits the reaction [Acetaminophen results in increased expression of IL6 protein] caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein] |
CTD |
PMID:21870829 PMID:27368151 PMID:27720869 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kif15 |
kinesin family member 15 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of KIF15 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kif20b |
kinesin family member 20B |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of KIF20B mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif2c |
kinesin family member 2C |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Thapsigargin results in increased expression of KIF2C mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased expression of LDHA protein] |
CTD |
PMID:21472895 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldhb |
lactate dehydrogenase B |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased expression of LDHB protein] |
CTD |
PMID:21472895 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
caffeic acid results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
caffeic acid results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MFN1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases activity |
EXP |
caffeic acid results in increased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases activity |
ISO EXP |
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [MPO protein results in increased metabolism of Hydrogen Peroxide]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MPO protein] caffeic acid inhibits the reaction [Ethanol results in increased activity of MPO protein]; NG-Nitroarginine Methyl Ester inhibits the reaction [caffeic acid inhibits the reaction [Ethanol results in increased activity of MPO protein]] caffeic acid results in decreased activity of MPO protein |
CTD |
PMID:22036979 PMID:24060682 PMID:33301711 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mrpl45 |
mitochondrial ribosomal protein L45 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MRPL45 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr10:82,308,650...82,320,474
Ensembl chr10:82,308,427...82,320,474
|
|
G |
Mrrf |
mitochondrial ribosome recycling factor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MRRF mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:19,487,124...19,543,911
Ensembl chr 3:19,487,182...19,543,908
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[caffeic acid co-treated with Zymosan] results in increased expression of COX2 protein; caffeic acid inhibits the reaction [Zymosan results in increased expression of COX2 protein] |
CTD |
PMID:30481570 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Ndp |
norrin cystine knot growth factor NDP |
increases expression |
ISO |
caffeic acid results in increased expression of NDP mRNA |
CTD |
PMID:19442820 |
|
NCBI chr X:5,796,487...5,820,934
Ensembl chr X:5,796,487...5,820,934
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of NOS2 protein] caffeic acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:29968957 PMID:31306686 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
caffeic acid results in increased expression of NOS3 mRNA |
CTD |
PMID:15740983 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of NOTCH1 mRNA] |
CTD |
PMID:29968957 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions decreases activity |
EXP |
caffeic acid inhibits the reaction [Caffeine results in decreased activity of NT5E protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of NT5E protein] |
CTD |
PMID:28465162 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Pdcd10 |
programmed cell death 10 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PDCD10 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:160,303,465...160,346,086
Ensembl chr 2:160,303,449...160,346,018
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
caffeic acid results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
caffeic acid results in increased expression of PIK3R1 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plk1 |
polo-like kinase 1 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of PLK1 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plk4 |
polo-like kinase 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of PLK4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:123,802,527...123,820,942
Ensembl chr 2:123,802,512...123,820,942
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
caffeic acid results in increased expression of PPARG mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prdx5 |
peroxiredoxin 5 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PRDX5 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PTGS2 mRNA] |
CTD |
PMID:19442820 PMID:22036979 PMID:31306686 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PTX3 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of RELA protein] |
CTD |
PMID:29968957 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of SCD1 protein |
CTD |
PMID:28576465 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of SERPINE1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sfxn4 |
sideroflexin 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of SFXN4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:259,976,480...259,998,778
Ensembl chr 1:259,976,481...259,998,754
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
increases expression |
ISO |
caffeic acid results in increased expression of SLC2A2 mRNA |
CTD |
PMID:33493636 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
caffeic acid results in increased expression of SLC2A4 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
increases expression |
ISO |
caffeic acid results in increased expression of SLC5A1 mRNA |
CTD |
PMID:33493636 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [SNCA protein binds to SNCA protein] |
CTD |
PMID:20150427 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of SREBF1 protein |
CTD |
PMID:28576465 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stk32a |
serine/threonine kinase 32A |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in decreased expression of STK32A mRNA |
CTD |
PMID:19442820 |
|
NCBI chr18:35,258,865...35,374,985
Ensembl chr18:35,259,052...35,369,451
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO |
SULT1A1 protein results in increased sulfation of caffeic acid |
CTD |
PMID:17433394 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases sulfation |
ISO |
SULT1C2 protein results in increased sulfation of caffeic acid |
CTD |
PMID:17433394 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of TNF mRNA caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Valproic Acid results in increased expression of TNF protein] caffeic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein] |
CTD |
PMID:21870829 PMID:22036979 PMID:27368151 PMID:29968957 PMID:31306686 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects expression multiple interactions |
ISO |
caffeic acid affects the expression of TP53 protein caffeic acid promotes the reaction [Thapsigargin results in decreased expression of TP53 mRNA] |
CTD |
PMID:11522280 PMID:19442820 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyr |
tyrosinase |
increases oxidation multiple interactions |
ISO |
TYR protein results in increased oxidation of caffeic acid [TYR protein results in increased oxidation of caffeic acid] which results in decreased abundance of Glutathione |
CTD |
PMID:20685355 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of UBE2C mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
caffeic acid results in decreased activity of UGT1A1 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation decreases activity |
ISO |
UGT1A3 protein results in increased glucuronidation of caffeic acid caffeic acid results in decreased activity of UGT1A3 protein |
CTD |
PMID:15117964 PMID:35868516 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases activity |
ISO |
caffeic acid results in decreased activity of UGT1A6 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
decreases activity |
ISO |
caffeic acid results in decreased activity of UGT1A9 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases activity |
ISO |
caffeic acid results in decreased activity of UGT2B17 protein |
CTD |
PMID:35868516 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases activity |
ISO |
caffeic acid results in decreased activity of UGT2B7 protein |
CTD |
PMID:35868516 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases secretion |
ISO |
caffeic acid results in decreased secretion of VEGFA protein |
CTD |
PMID:27378625 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [XDH protein results in increased chemical synthesis of Uric Acid]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of XDH protein] |
CTD |
PMID:22036979 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of AKT1 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of AKT1 mRNA] corilagin results in decreased expression of AKT1 protein |
CTD |
PMID:34369273 PMID:34605098 PMID:35084093 PMID:35103375 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of BAX protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2 protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bsg |
basigin |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BSG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP3 protein] corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]] |
CTD |
PMID:34605098 PMID:35103375 PMID:37394652 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP9 protein] |
CTD |
PMID:35103375 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased activity of CAT protein]; corilagin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA] |
CTD |
PMID:30582900 PMID:34605098 PMID:35103375 PMID:35307913 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of FABP3 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:35307913 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA |
CTD |
PMID:35307913 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HIF1A mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HMGB1 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased activity of HMGCR protein] |
CTD |
PMID:34605098 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of IL6 protein] corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]] corilagin results in decreased expression of IL6 protein |
CTD |
PMID:34369273 PMID:34605098 PMID:35084093 PMID:37394652 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Streptozocin results in increased secretion of INS1 protein] |
CTD |
PMID:30582900 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of LDHA mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mb |
myoglobin |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of MB protein] |
CTD |
PMID:34369273 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:35307913 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:35307913 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
corilagin results in decreased expression of NFKB1 protein |
CTD |
PMID:35084093 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
corilagin results in decreased expression of NOS2 protein corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]] |
CTD |
PMID:35084093 PMID:37394652 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of NPPB protein] |
CTD |
PMID:34369273 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
corilagin inhibits the reaction [1-naphthyl isothiocyanate decreases expression of nr1h4 mRNA and protein in rat liver]; corilagin increases expression of nr1h4 mRNA and protein in rat embryonic liver cells |
RGD |
PMID:29235094 |
RGD:15042872 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of PIK3CG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of PPARG protein] |
CTD |
PMID:34605098 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
corilagin results in decreased expression of PTGS2 protein corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]] |
CTD |
PMID:35084093 PMID:37394652 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of SLC16A3 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of TLR2 mRNA]; corilagin inhibits the reaction [Morphine results in increased expression of TLR2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
ISO EXP |
corilagin results in decreased secretion of TNF protein corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]] corilagin results in decreased expression of TNF protein corilagin inhibits the reaction [Doxorubicin results in increased expression of TNF protein] |
CTD |
PMID:12628509 PMID:34369273 PMID:34605098 PMID:35084093 PMID:37394652 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of TNNI3 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
|
G |
Acp3 |
acid phosphatase 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ACP3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] |
CTD |
PMID:32971123 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of CYBA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of MYH7 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NCF2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPB mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:38356441 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of AGTR1 protein] |
CTD |
PMID:38356441 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of AIFM1 protein |
CTD |
PMID:23554011 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Ellagic Acid results in increased phosphorylation of AKT1 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of AKT1 protein] |
CTD |
PMID:26986492 PMID:35236242 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] Ellagic Acid binds to ALB protein |
CTD |
PMID:6343536 PMID:25247703 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alkbh2 |
alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of ALKBH2 protein |
CTD |
PMID:31088072 |
|
NCBI chr12:42,494,187...42,500,929
Ensembl chr12:42,496,300...42,500,914
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Ellagic Acid results in increased expression of ALPL mRNA |
CTD |
PMID:38145796 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of APAF1 mRNA Ellagic Acid results in increased expression of APAF1 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Aluminum Chloride results in increased expression of APP protein] |
CTD |
PMID:34944019 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASCL1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASNS mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATF3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATG5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
Ellagic Acid results in increased expression of BAD protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA] Ellagic Acid results in increased expression of BAX mRNA |
CTD |
PMID:29854611 PMID:35179410 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of BCL2 protein Ellagic Acid results in decreased expression of BCL2 mRNA Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA] [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA] |
CTD |
PMID:20103723 PMID:22386815 PMID:29854611 PMID:35179410 PMID:35236242 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BMP6 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brf1 |
BRF1 general transcription factor IIIB subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BRF1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CALR mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions increases activity decreases activity decreases expression |
ISO EXP |
Ellagic Acid results in increased expression of CASP3 mRNA Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]; Ellagic Acid promotes the reaction [sinapinic acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]]; sinapinic acid promotes the reaction [Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]] Ellagic Acid results in increased expression of and results in increased activity of CASP3 protein Ellagic Acid results in increased activity of CASP3 protein Ellagic Acid results in decreased activity of CASP3 protein Ellagic Acid results in decreased expression of CASP3 mRNA |
CTD |
PMID:12002526 PMID:22386815 PMID:23554011 PMID:23811531 PMID:28815802 PMID:29854611 PMID:34661493 PMID:34944019 PMID:35236242 PMID:38356441 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Ellagic Acid results in increased expression of and results in increased activity of CASP9 protein |
CTD |
PMID:23554011 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Ellagic Acid results in increased activity of CAT protein Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] |
CTD |
PMID:20074268 PMID:24877639 PMID:29864931 PMID:35236242 PMID:36108929 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases secretion |
ISO |
Ellagic Acid results in decreased secretion of CCL2 protein |
CTD |
PMID:20816778 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccng1 |
cyclin G1 |
decreases expression |
EXP |
ellagic acid inhibits the reaction [estrogen increases expression of Ccng1 mRNA and protein in rat mammary tissue] |
RGD |
PMID:23791885 |
RGD:151356928 |
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CD14 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CDK1 protein |
CTD |
PMID:23554011 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA] [Ellagic Acid co-treated with Quercetin] results in increased expression of CDKN1A mRNA; Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]] Ellagic Acid results in increased expression of CDKN1A protein |
CTD |
PMID:15735102 PMID:20103723 PMID:23554011 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Ellagic Acid results in increased expression of COL1A1 mRNA; Ellagic Acid results in increased expression of COL1A1 protein |
CTD |
PMID:38145796 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:21762681 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein] |
CTD |
PMID:32971123 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of CYBA mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of CYP1A1 mRNA Ellagic Acid results in decreased activity of CYP1A1 protein |
CTD |
PMID:19329757 PMID:20816778 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Ellagic Acid results in decreased activity of CYP1B1 protein [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:19329757 PMID:20103723 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Daxx |
death-domain associated protein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DAXX mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DFFA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
E4f1 |
E4F transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of E4F1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:13,471,478...13,495,018
Ensembl chr10:13,474,456...13,485,974
|
|
G |
Egr3 |
early growth response 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of EGR3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Endog |
endonuclease G |
increases expression |
ISO |
Ellagic Acid results in increased expression of ENDOG protein |
CTD |
PMID:23554011 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EP300 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EPS15 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
increases expression |
ISO |
Ellagic Acid results in increased expression of EZH1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
F12 |
coagulation factor XII |
multiple interactions increases activity |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] |
CTD |
PMID:6343536 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FGFR1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Flna |
filamin A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FLNA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FN1 protein] |
CTD |
PMID:24877639 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:20103723 PMID:32971123 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased activity of GAL protein] |
CTD |
PMID:27965107 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gpld1 |
glycosylphosphatidylinositol specific phospholipase D1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of GPLD1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:40,084,427...40,132,035
Ensembl chr17:40,084,617...40,126,939
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GPT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of GPT protein] Ellagic Acid inhibits the reaction [Diquat results in increased activity of GPT protein] |
CTD |
PMID:24877639 PMID:29935397 PMID:35268077 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP ISO |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] Ellagic Acid inhibits the reaction [Diquat results in decreased expression of GPX1 mRNA] |
CTD |
PMID:29935397 PMID:35268077 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of GSR protein] |
CTD |
PMID:24877639 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GSTA4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects expression |
EXP |
Ellagic Acid affects the expression of GSTT1 protein |
CTD |
PMID:9855024 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtf2e2 |
general transcription factor IIE subunit 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2E2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:58,399,307...58,449,467
Ensembl chr16:58,399,107...58,449,371
|
|
G |
Gtf2h4 |
general transcription factor 2H subunit 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2H4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:21762681 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of HIF1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of HMOX1 mRNA; Ellagic Acid results in increased expression of HMOX1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of HMOX1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 protein |
CTD |
PMID:22386815 PMID:23546295 PMID:35268077 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene] |
CTD |
PMID:20103723 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Ier2 |
immediate early response 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IER2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG protein] |
CTD |
PMID:29854611 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IGFBP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of IL1B mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] Ellagic Acid inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:18377686 PMID:20816778 PMID:21762681 PMID:24877639 PMID:27965107 PMID:29455002 PMID:29854611 PMID:29864931 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IL1R1 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL6 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL6 protein] |
CTD |
PMID:21762681 PMID:24877639 PMID:27965107 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
increases expression |
ISO |
Ellagic Acid results in increased expression of INPP5D mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
|
|
G |
Iqgap2 |
IQ motif containing GTPase activating protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IQGAP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279
|
|
G |
Irf9 |
interferon regulatory factor 9 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IRF9 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of JUN mRNA; Ellagic Acid results in decreased expression of JUN protein modified form |
CTD |
PMID:23811531 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of KLK3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
increases expression |
ISO |
Ellagic Acid results in increased expression of LITAF mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Map1a |
microtubule-associated protein 1A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP3K1 mRNA; Ellagic Acid results in decreased expression of MAP3K1 protein |
CTD |
PMID:23811531 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32971123 PMID:38356441 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
increases expression |
ISO |
Ellagic Acid results in increased expression of MAPK11 mRNA |
CTD |
PMID:23811531 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of MAPK14 protein] |
CTD |
PMID:27965107 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32971123 PMID:38356441 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:15735102 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15735102 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Ellagic Acid results in decreased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir140 |
microRNA 140 |
multiple interactions |
EXP |
ellagic acid inhibits the reaction [hypoxia and acute myocardial infarction decreases expression of mir140 RNA in cardiac muscle cells] |
RGD |
PMID:28922712 |
RGD:329347824 |
NCBI chr19:35,465,577...35,465,675
Ensembl chr19:35,465,577...35,465,675
|
|
G |
Mmd |
monocyte to macrophage differentiation-associated |
increases expression |
ISO |
Ellagic Acid results in increased expression of MMD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein; zinc chloride inhibits the reaction [Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein] Ellagic Acid results in decreased expression of MMP2 mRNA Ellagic Acid results in decreased activity of MMP2 protein |
CTD |
PMID:21573219 PMID:35179410 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of MMP9 mRNA Ellagic Acid results in decreased activity of MMP9 protein |
CTD |
PMID:35179410 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of MYH7 mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NCF2 mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:32971123 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions increases expression affects response to substance |
ISO EXP |
Ellagic Acid affects the localization of NFE2L2 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein] Ellagic Acid results in increased expression of NFE2L2 mRNA [Ellagic Acid co-treated with Diquat] results in increased expression of NFE2L2 mRNA; Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NFE2L2 mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of NFE2L2 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of and affects the localization of NFE2L2 protein; [Paraquat co-treated with Ellagic Acid] results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of and affects the localization of NFE2L2 protein Ellagic Acid results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of NFE2L2 protein NFE2L2 protein affects the susceptibility to Ellagic Acid |
CTD |
PMID:22386815 PMID:23546295 PMID:30503583 PMID:35236242 PMID:35268077 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NFKB2 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nnat |
neuronatin |
increases expression |
ISO |
Ellagic Acid results in increased expression of NNAT mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Nop56 |
NOP56 ribonucleoprotein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NOP56 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] Ellagic Acid results in decreased expression of NOS2 mRNA |
CTD |
PMID:28815802 PMID:35179410 PMID:38356441 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of NPAS2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPA mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPB mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of NQO1 mRNA; Ellagic Acid results in increased expression of NQO1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NQO1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 protein |
CTD |
PMID:23546295 PMID:35268077 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Ellagic Acid results in increased activity of NR1I3 protein |
CTD |
PMID:21821919 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PARG protein |
CTD |
PMID:19840838 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] |
CTD |
PMID:25247703 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA] |
CTD |
PMID:20103723 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased nitrosation of and results in decreased activity of PDIA2 protein] |
CTD |
PMID:25247703 |
|
NCBI chr10:15,215,824...15,218,937
Ensembl chr10:15,215,824...15,220,931
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PLA2G2A mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Plp2 |
proteolipid protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PLP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:14,834,249...14,837,648
Ensembl chr X:14,834,231...14,838,514
|
|
G |
Pml |
PML nuclear body scaffold |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PML mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PPARD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Ellagic Acid results in increased expression of PPARG protein |
CTD |
PMID:23811531 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of PPARGC1A mRNA] Ellagic Acid results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:30503583 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PRKG1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Ptn |
pleiotrophin |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of PTN mRNA Ellagic Acid results in increased expression of PTN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Ptprn2 |
protein tyrosine phosphatase, receptor type N2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PTPRN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575
|
|
G |
Ran |
RAN, member RAS oncogene family |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RAN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 protein] |
CTD |
PMID:27965107 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of RECK mRNA; Ellagic Acid results in increased expression of RECK protein zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK mRNA]; zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK protein] |
CTD |
PMID:21573219 |
|
NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of RELA mRNA Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein] Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RELA protein] |
CTD |
PMID:12002526 PMID:24877639 PMID:27473819 PMID:27965107 PMID:32971123 PMID:35236242 PMID:38356441 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgs5 |
regulator of G-protein signaling 5 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RGS5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of RUNX2 mRNA; Ellagic Acid results in increased expression of RUNX2 protein |
CTD |
PMID:38145796 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SCD mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Septin2 |
septin 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of SEPTIN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 mRNA]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 protein] |
CTD |
PMID:34944019 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] |
CTD |
PMID:29935397 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SOD3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Ellagic Acid results in increased expression of SP7 mRNA; Ellagic Acid results in increased expression of SP7 protein |
CTD |
PMID:38145796 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of SPP1 mRNA; Ellagic Acid results in increased expression of SPP1 protein |
CTD |
PMID:38145796 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein] |
CTD |
PMID:32971123 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of STAR mRNA Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of STAR mRNA] |
CTD |
PMID:30503583 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression decreases expression |
ISO |
Ellagic Acid results in increased expression of STAT3 mRNA Ellagic Acid results in decreased expression of STAT3 mRNA |
CTD |
PMID:12002526 PMID:20816778 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Taf1c |
TATA-box binding protein associated factor, RNA polymerase 1 subunit C |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TAF1C mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:47,652,451...47,658,971
Ensembl chr19:47,652,452...47,658,971
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
Ellagic Acid results in increased expression of TCF12 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions increases expression |
ISO EXP |
Ellagic Acid inhibits the reaction [Estradiol results in increased expression of TERT mRNA alternative form] Ellagic Acid inhibits the reaction [phosalone results in decreased activity of TERT protein] Ellagic Acid results in increased expression of TERT mRNA alternative form |
CTD |
PMID:19501078 PMID:27965107 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TFAM mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TGFB1 mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein] |
CTD |
PMID:12002526 PMID:24877639 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [TNF protein results in increased activity of and affects the secretion of CXCL8 protein] Ellagic Acid results in decreased expression of TNF mRNA |
CTD |
PMID:21762681 PMID:24877639 PMID:27473819 PMID:27965107 PMID:28815802 PMID:29455002 PMID:29854611 PMID:29864931 PMID:35179410 PMID:35236242 PMID:36108929 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein] Ellagic Acid binds to TNFRSF11A protein |
CTD |
PMID:32971123 |
|
NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid binds to TNFSF11 protein |
CTD |
PMID:32971123 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] |
CTD |
PMID:21762681 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TP53 mRNA; Ellagic Acid results in increased expression of TP53 protein Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein] |
CTD |
PMID:15735102 PMID:23554011 PMID:27965107 PMID:35179410 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of UGP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
|
|
G |
Usp4 |
ubiquitin specific peptidase 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of USP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:109,035,402...109,079,382
Ensembl chr 8:109,036,099...109,080,427
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of VEGFA protein] |
CTD |
PMID:35236242 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of WARS1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of WEE1 protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of ZBTB16 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
G |
Zmym2 |
zinc finger MYM-type containing 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ZMYM2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:31,035,835...31,108,945
Ensembl chr15:31,035,838...31,109,357
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases response to substance |
ISO |
GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Ethacrynic Acid] |
CTD |
PMID:10900222 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport |
ISO |
ABCC2 protein results in increased transport of Ethacrynic Acid |
CTD |
PMID:16316932 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of AKR1C1 mRNA |
CTD |
PMID:9973208 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [4-nitrobenzaldehyde affects the reduction of AKR7A5 protein] |
CTD |
PMID:12604212 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
ISO |
Ethacrynic Acid results in increased expression of BCL2L1 protein [arsenic trioxide co-treated with Ethacrynic Acid] results in increased expression of BCL2L1 protein |
CTD |
PMID:23082001 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in decreased expression of BIRC5 protein |
CTD |
PMID:23082001 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein; [MCL1 mutant form results in increased susceptibility to [Ethacrynic Acid co-treated with arsenic trioxide]] which results in increased cleavage of CASP3 protein; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein] |
CTD |
PMID:23082001 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP8 protein Ethacrynic Acid results in increased cleavage of CASP8 protein |
CTD |
PMID:23082001 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO |
Ethacrynic Acid results in increased cleavage of CASP9 protein arsenic trioxide promotes the reaction [Ethacrynic Acid results in increased cleavage of CASP9 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein] |
CTD |
PMID:23082001 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT mutant form promotes the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]] |
CTD |
PMID:23082001 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [CBR1 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] |
CTD |
PMID:11306090 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of CCND1 mRNA |
CTD |
PMID:20011538 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of CDKN1A mRNA |
CTD |
PMID:25817893 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of CFLAR protein] |
CTD |
PMID:23082001 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Ethacrynic Acid results in increased expression of CYP1A1 mRNA Ethacrynic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:9973208 PMID:18493746 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Ethacrynic Acid results in increased expression of DDIT3 mRNA]; Glutathione inhibits the reaction [Ethacrynic Acid results in increased expression of DDIT3 mRNA] Ethacrynic Acid results in increased expression of DDIT3 mRNA; Ethacrynic Acid results in increased expression of DDIT3 protein |
CTD |
PMID:17171638 PMID:25817893 PMID:35724838 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of FN1 mRNA |
CTD |
PMID:20011538 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of FOS mRNA |
CTD |
PMID:10407097 PMID:12946577 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fzd5 |
frizzled class receptor 5 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of FZD5 mRNA |
CTD |
PMID:20011538 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Ethacrynic Acid |
CTD |
PMID:10900222 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Ethacrynic Acid |
CTD |
PMID:10900222 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases response to substance increases expression multiple interactions affects metabolic processing |
ISO EXP |
GSTA1 protein results in decreased susceptibility to Ethacrynic Acid Ethacrynic Acid results in increased expression of GSTA1 mRNA [GSTA1 protein binds to GSTA2 protein] which affects the metabolism of Ethacrynic Acid GSTA1 protein affects the metabolism of Ethacrynic Acid analog |
CTD |
PMID:1985777 PMID:9799558 PMID:9877184 PMID:12781783 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
affects metabolic processing multiple interactions |
EXP |
GSTA2 protein affects the metabolism of Ethacrynic Acid [GSTA1 protein binds to GSTA2 protein] which affects the metabolism of Ethacrynic Acid |
CTD |
PMID:9877184 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression affects metabolic processing |
EXP |
Ethacrynic Acid results in increased expression of GSTA4 mRNA; Ethacrynic Acid results in increased expression of GSTA4 protein GSTA4 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:2619714 PMID:9799558 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects metabolic processing |
ISO |
GSTM1 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:12069689 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity affects metabolic processing decreases response to substance increases expression multiple interactions |
ISO EXP |
Ethacrynic Acid analog results in decreased activity of GSTP1 protein; Ethacrynic Acid results in decreased activity of GSTP1 protein GSTP1 protein affects the metabolism of Ethacrynic Acid GSTP1 protein results in decreased susceptibility to Ethacrynic Acid GSTP1 protein affects the metabolism of Ethacrynic Acid analog Ethacrynic Acid results in increased expression of GSTP1 protein Ethacrynic Acid binds to and results in decreased activity of GSTP1 protein; Ethacrynic Acid inhibits the reaction [Chlorophyllides inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]]; Ethacrynic Acid inhibits the reaction [GSTP1 protein affects the metabolism of Isotretinoin]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Ethacrynic Acid]; GSTP1 protein results in decreased susceptibility to [arsenic trioxide co-treated with Ethacrynic Acid]; Pyrimethamine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid]; Quinidine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid]; Quinine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid]; Tetracycline inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid] |
CTD |
PMID:2619714 PMID:2747627 PMID:9463521 PMID:9806904 PMID:9877184 PMID:10900222 PMID:11807801 PMID:12781783 PMID:14556662 PMID:15911318 PMID:15999103 PMID:23082001 PMID:23769903 More...
|
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
affects metabolic processing |
EXP |
GSTT2 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:2114406 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
affects metabolic processing |
ISO |
GSTZ1 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:9396740 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Acetylcysteine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Glutathione inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Glutathione inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 protein] Ethacrynic Acid results in increased expression of HMOX1 mRNA; Ethacrynic Acid results in increased expression of HMOX1 protein |
CTD |
PMID:20934533 PMID:25817893 PMID:26945724 PMID:35724838 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Ethacrynic Acid results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Ethacrynic Acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:35724838 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; Ethacrynic Acid inhibits the reaction [IL1B protein affects the localization of RELA protein]; Ethacrynic Acid inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Ethacrynic Acid inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:35724838 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Ethacrynic Acid co-treated with arsenic trioxide] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [[Ethacrynic Acid co-treated with arsenic trioxide] results in increased phosphorylation of JUN protein] |
CTD |
PMID:23082001 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression affects binding |
ISO |
Ethacrynic Acid results in decreased expression of LEF1 mRNA Ethacrynic Acid binds to LEF1 protein |
CTD |
PMID:20011538 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of MAP2K1 protein |
CTD |
PMID:14556662 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of MAPK14 protein |
CTD |
PMID:14556662 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of MAPK3 protein |
CTD |
PMID:14556662 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of MAPK8 protein |
CTD |
PMID:14556662 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
ISO |
[MCL1 mutant form results in increased susceptibility to [Ethacrynic Acid co-treated with arsenic trioxide]] which results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; CAT mutant form promotes the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; MCL1 mutant form results in increased susceptibility to [Ethacrynic Acid co-treated with arsenic trioxide]; pyrazolanthrone inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]] |
CTD |
PMID:23082001 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization affects response to substance increases expression |
ISO |
NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Ethacrynic Acid] Ethacrynic Acid results in increased expression of and affects the localization of NFE2L2 protein; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]] [NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Ethacrynic Acid Ethacrynic Acid results in increased expression of NFE2L2 protein |
CTD |
PMID:19303893 PMID:20932822 PMID:20934533 PMID:25817893 PMID:26945724 PMID:35724838 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; Ethacrynic Acid inhibits the reaction [TNF protein affects the localization of NFKBIA protein] |
CTD |
PMID:35724838 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of NGF mRNA |
CTD |
PMID:10407097 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Ethacrynic Acid promotes the reaction [Potassium Cyanide results in increased expression of NOS2 protein] |
CTD |
PMID:16933320 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein] |
CTD |
PMID:23082001 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [IL1B protein affects the localization of RELA protein]; Ethacrynic Acid inhibits the reaction [TNF protein affects the localization of RELA protein] |
CTD |
PMID:35724838 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases activity multiple interactions |
ISO |
Ethacrynic Acid results in decreased activity of SLC12A2 protein Ethacrynic Acid inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium] |
CTD |
PMID:29959396 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of SRXN1 protein |
CTD |
PMID:35724838 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [TNF protein affects the localization of NFKBIA protein]; Ethacrynic Acid inhibits the reaction [TNF protein affects the localization of RELA protein]; Ethacrynic Acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Ethacrynic Acid inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:35724838 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression multiple interactions |
ISO |
Ethacrynic Acid results in increased expression of TNFAIP3 protein Ethacrynic Acid inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein]; Ethacrynic Acid inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:35724838 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tp53 |
tumor protein p53 |
affects localization |
ISO |
Ethacrynic Acid affects the localization of TP53 protein |
CTD |
PMID:25817893 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in decreased expression of XIAP protein |
CTD |
PMID:23082001 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of AKT1 protein |
CTD |
PMID:24892518 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Cdh2 |
cadherin 2 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDH2 protein |
CTD |
PMID:24892518 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDK2 protein |
CTD |
PMID:24892518 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDK4 protein |
CTD |
PMID:24892518 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
affects expression multiple interactions |
ISO |
ethyl caffeate affects the expression of ERBB2 protein ethyl caffeate affects the phosphorylation of and affects the activity of ERBB2 protein |
CTD |
PMID:24892518 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
affects expression |
ISO |
ethyl caffeate affects the expression of FGFR1 protein |
CTD |
PMID:24892518 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Ilk |
integrin-linked kinase |
affects expression |
ISO |
ethyl caffeate affects the expression of ILK protein |
CTD |
PMID:24892518 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
ethyl caffeate affects the expression of [ITGA3 protein binds to ITGB1 protein] |
CTD |
PMID:24892518 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ethyl caffeate affects the expression of [ITGA3 protein binds to ITGB1 protein] |
CTD |
PMID:24892518 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Kdr |
kinase insert domain receptor |
affects expression |
ISO |
ethyl caffeate affects the expression of KDR protein |
CTD |
PMID:24892518 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of MAPK1 protein |
CTD |
PMID:24892518 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of MAPK3 protein |
CTD |
PMID:24892518 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects phosphorylation |
ISO |
ethyl caffeate affects the phosphorylation of RB1 protein |
CTD |
PMID:24892518 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ABCC1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ABCD1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ABHD16A mRNA |
CTD |
PMID:19376150 |
|
NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ACADS mRNA |
CTD |
PMID:19376150 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acbd4 |
acyl-CoA binding domain containing 4 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ACBD4 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:88,048,058...88,062,612
Ensembl chr10:88,048,108...88,058,500
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO |
[Hypochlorous Acid co-treated with Sodium Nitrite] results in decreased activity of ACHE protein; Curcumin inhibits the reaction [Hypochlorous Acid results in decreased activity of ACHE protein] |
CTD |
PMID:12414318 PMID:36924976 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adrm1 |
ADRM1 26S proteasome ubiquitin receptor |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ADRM1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 3:167,265,435...167,270,197
Ensembl chr 3:167,265,296...167,270,195
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of AFP mRNA |
CTD |
PMID:19376150 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agrn |
agrin |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of AGRN mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of AKR1A1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of AKR1B1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of AKR7A5 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:18156441 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Amotl1 |
angiomotin-like 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of AMOTL1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:11,348,651...11,467,564
Ensembl chr 8:11,353,674...11,467,573
|
|
G |
Ampd1 |
adenosine monophosphate deaminase 1 |
increases activity multiple interactions |
ISO |
Hypochlorous Acid results in increased activity of AMPD1 protein Curcumin inhibits the reaction [Hypochlorous Acid results in increased activity of AMPD1 protein] |
CTD |
PMID:36924976 |
|
NCBI chr 2:190,598,707...190,619,938
Ensembl chr 2:190,598,700...190,619,938
|
|
G |
Angel2 |
angel homolog 2 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ANGEL2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr13:102,509,111...102,529,501
Ensembl chr13:102,510,589...102,529,493
|
|
G |
Ankib1 |
ankyrin repeat and IBR domain containing 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ANKIB1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 4:30,333,678...30,457,781
Ensembl chr 4:30,333,677...30,457,781
|
|
G |
Ankrd11 |
ankyrin repeat domain containing 11 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ANKRD11 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr19:50,940,284...51,098,962
Ensembl chr19:50,940,299...51,098,962
|
|
G |
Ankrd13d |
ankyrin repeat domain 13D |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ANKRD13D mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:201,565,712...201,577,987
Ensembl chr 1:201,565,712...201,577,933
|
|
G |
Ap1g2 |
adaptor related protein complex 1 subunit gamma 2 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of AP1G2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr15:28,571,571...28,579,421
Ensembl chr15:28,571,568...28,589,004
|
|
G |
Ap3s2 |
adaptor related protein complex 3 subunit sigma 2 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of AP3S2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:133,818,825...133,859,269
Ensembl chr 1:133,818,825...133,859,322
|
|
G |
Apeh |
acylaminoacyl-peptide hydrolase |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of APEH mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:108,773,791...108,782,903
Ensembl chr 8:108,773,794...108,782,933
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions increases expression increases activity |
ISO |
Acetylcysteine inhibits the reaction [Hypochlorous Acid results in increased expression of APEX1 protein] Hypochlorous Acid results in increased activity of APEX1 protein |
CTD |
PMID:12231548 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Api5 |
apoptosis inhibitor 5 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of API5 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 3:80,378,096...80,403,259
Ensembl chr 3:80,378,096...80,403,264
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[Hypochlorous Acid results in increased oxidation of [APOA1 protein binds to Lipids]] which results in decreased activity of LCAT protein; Hypochlorous Acid results in increased oxidation of [APOA1 protein binds to Lipids] |
CTD |
PMID:33861588 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Appbp2 |
amyloid beta precursor protein binding protein 2 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of APPBP2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:70,057,774...70,099,877
Ensembl chr10:70,057,774...70,099,835
|
|
G |
Arcn1 |
archain 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ARCN1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:45,057,617...45,082,224
Ensembl chr 8:45,057,619...45,082,247
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ARHGAP24 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ARHGEF1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ARIH1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:59,777,378...59,879,762
Ensembl chr 8:59,777,379...59,880,245
|
|
G |
Arl2 |
ARF like GTPase 2 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of ARL2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:203,434,129...203,446,156
Ensembl chr 1:203,434,129...203,446,119
|
|
G |
Atxn3 |
ataxin 3 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of ATXN3 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of B3GAT3 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
Bace1 |
beta-secretase 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BACE1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BCKDK mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of BCLAF1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of BLVRB mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Brd4 |
bromodomain containing 4 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BRD4 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539
|
|
G |
Brd8 |
bromodomain containing 8 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BRD8 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr18:26,204,892...26,229,999
Ensembl chr18:26,181,732...26,229,884
|
|
G |
Bri3 |
brain protein I3 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BRI3 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr12:10,341,007...10,364,655
Ensembl chr12:10,341,011...10,364,735
|
|
G |
Brms1 |
BRMS1, transcriptional repressor and anoikis regulator |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BRMS1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:202,345,766...202,355,028
Ensembl chr 1:202,345,704...202,355,028
|
|
G |
Btbd2 |
BTB domain containing 2 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of BTBD2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 7:9,058,609...9,075,341
Ensembl chr 7:9,060,788...9,075,344
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of BZW1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 9:59,930,672...59,944,468
Ensembl chr 9:59,930,744...59,944,430
|
|
G |
Cab39 |
calcium binding protein 39 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CAB39 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Camk1d |
calcium/calmodulin-dependent protein kinase ID |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CAMK1D mRNA |
CTD |
PMID:19376150 |
|
NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556
|
|
G |
Canx |
calnexin |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CANX mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Capn5 |
calpain 5 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CAPN5 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:152,416,252...152,472,923
Ensembl chr 1:152,416,252...152,472,923
|
|
G |
Car12 |
carbonic anhydrase 12 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CAR12 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Cat |
catalase |
multiple interactions increases activity increases expression |
ISO |
CAT protein modified form inhibits the reaction [Hypochlorous Acid results in increased expression of GCLC mRNA]; CAT protein modified form inhibits the reaction [Hypochlorous Acid results in increased expression of NFE2L2 mRNA] Hypochlorous Acid results in increased activity of CAT protein Curcumin inhibits the reaction [Hypochlorous Acid results in increased activity of CAT protein] Hypochlorous Acid results in increased expression of CAT mRNA |
CTD |
PMID:17980396 PMID:19376150 PMID:36924976 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CCND3 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Cd47 |
Cd47 molecule |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CD47 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CDC42 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CDCA7L mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888
|
|
G |
Cdk5rap3 |
CDK5 regulatory subunit associated protein 3 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CDK5RAP3 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:81,894,393...81,903,581
Ensembl chr10:81,894,393...81,903,590
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CDK6 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CDK7 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 2:31,840,558...31,865,422
Ensembl chr 2:31,840,558...31,865,383
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CDS1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681
|
|
G |
Cds2 |
CDP-diacylglycerol synthase 2 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CDS2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 3:119,514,963...119,553,555
Ensembl chr 3:119,515,000...119,553,541
|
|
G |
Cep43 |
centrosomal protein 43 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CEP43 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:52,533,418...52,564,025
Ensembl chr 1:52,533,428...52,563,923
|
|
G |
Cep76 |
centrosomal protein 76 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CEP76 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr18:61,174,514...61,208,512
Ensembl chr18:61,178,310...61,208,504
|
|
G |
Cerk |
ceramide kinase |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CERK mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 7:117,225,855...117,269,436
Ensembl chr 7:117,225,855...117,268,759
|
|
G |
Chd3 |
chromodomain helicase DNA binding protein 3 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CHD3 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:54,063,629...54,090,030
Ensembl chr10:54,063,629...54,090,047
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CHD4 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Chit1 |
chitinase 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CHIT1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr13:45,565,841...45,613,593
Ensembl chr13:45,593,845...45,613,592
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CHORDC1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Clec4d |
C-type lectin domain family 4, member D |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CLEC4D mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 4:156,589,591...156,599,279
Ensembl chr 4:156,589,792...156,598,848
|
|
G |
Cln6 |
CLN6, transmembrane ER protein |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CLN6 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360
|
|
G |
Clta |
clathrin, light chain A |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CLTA mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Coro1a |
coronin 1A |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CORO1A mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Ctdsp1 |
CTD small phosphatase 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CTDSP1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 9:75,973,694...75,979,298
Ensembl chr 9:75,973,962...75,979,297
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CTNNBIP1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 5:159,961,961...160,010,942
Ensembl chr 5:159,961,928...160,010,939
|
|
G |
Ctns |
cystinosin, lysosomal cystine transporter |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CTNS mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:57,801,551...57,817,213
Ensembl chr10:57,801,456...57,817,120
|
|
G |
Ctsb |
cathepsin B |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of CTSB mRNA |
CTD |
PMID:19376150 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cul5 |
cullin 5 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CUL5 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:54,012,963...54,066,751
Ensembl chr 8:54,016,006...54,066,666
|
|
G |
Cyp20a1 |
cytochrome P450, family 20, subfamily a, polypeptide 1 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of CYP20A1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 9:61,755,804...61,805,123
Ensembl chr 9:61,755,790...61,805,123
|
|
G |
Dab2 |
DAB adaptor protein 2 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of DAB2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of DDIT3 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx10 |
DEAD-box helicase 10 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of DDX10 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:53,488,656...53,643,373
Ensembl chr 8:53,488,656...53,643,373
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of DDX3X mRNA |
CTD |
PMID:19376150 |
|
NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Dennd1a |
DENN domain containing 1A |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of DENND1A mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062
|
|
G |
Dhx33 |
DEAH-box helicase 33 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of DHX33 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr10:55,708,102...55,724,618
Ensembl chr10:55,705,756...55,724,567
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of DLST mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dnaja2 |
DnaJ heat shock protein family (Hsp40) member A2 |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of DNAJA2 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Hypochlorous Acid results in decreased expression of DNMT1 mRNA |
CTD |
PMID:19376150 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
increases expression |
ISO |
Hypochlorous Acid results in increased expression of DNMT3L mRNA |
CTD |
| |